Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
  • M&A / Deals

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling

BioSpace

A trifecta of newly inked tech partnerships--from Eli Lilly, Bristol Myers Squibb and Incyte--exemplify the increasingly central role that AI is playing in drug development.

Read full story

pharminent May 21, 2026 (Last updated: May 21, 2026)

BioSpace

A trifecta of newly inked tech partnerships–from Eli Lilly, Bristol Myers Squibb and Incyte–exemplify the increasingly central role that AI is playing in drug development.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication
Next: Lilly’s ‘triple G’ retatrutide aces crucial obesity trial

Related Stories

  • M&A / Deals

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

pharminent July 10, 2026
  • M&A / Deals

GSK ends dementia alliance with Alector after setbacks

pharminent July 9, 2026
  • M&A / Deals

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

pharminent July 8, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.